NCT06093126View on ClinicalTrials.gov

Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 11, 2023

Primary Completion Date

December 11, 2028

Study Completion Date

December 11, 2028

Conditions
InsomniaDementiaFrontotemporal Dementia
Interventions
DRUG

Lemborexant 5 MG

The participant will receive 8 weeks of treatment Week 1 = placebo Week 2 = lemborexant 5mg Week 3 = lemborexant 10 mg Week 4 = placebo Week 5 = lemborexant 10 mg Week 6 = placebo Week 7 = placebo Week 8 = lemborexant 10 mg

Trial Locations (1)

B3H 2E1

RECRUITING

Nova Scotia Health, Halifax

All Listed Sponsors
lead

Nova Scotia Health Authority

OTHER